Previous 10 | Next 10 |
- Ex vivo data support the high frequency of myeloid cells in tumors, even when T cells are not present - REDWOOD CITY, Calif., May 27, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncol...
3 Hot Penny Stocks to Watch in May 2022 Finding hot penny stocks to buy can be tricky. But if you put in the work, it can be very rewarding. One of the biggest factors to understand is researching the penny stocks on your list. This will give you a good idea of the companies you are...
Bolt Biotherapeutics press release (NASDAQ:BOLT): Q1 GAAP EPS of -$0.64 beats by $0.08. Revenue of $0.81M beats by $0.31M. Cash, cash equivalents, and marketable securities were $246.8 million as of March 31, 2022 – Cash on hand, which includes long-term marketable securities, is expec...
– BDC-1001 monotherapy and OPDIVO ® combination trials progressing toward data readouts in second half of 2022 – C ash balance of $246.8 million expected to fund key milestones and operations into 2024 REDWOOD CITY, Calif., May 12...
REDWOOD CITY, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology therapeutics that combine the targeting precision of antibodies with the power of both the innate and adaptive immun...
Shares of Bolt Biotherapeutics Inc. (NASDAQ:BOLT) traded today at $42.41, eclipsing its 52-week high. Approximately 4.3 million shares have changed hands today, as compared to an average 30-day volume of 184,000 shares. Bolt Biotherapeutics Inc. (NASDAQ:BOLT) is currently priced 7.9% abo...
Bolt Therapeutics (NASDAQ:BOLT) has filed for a $250M mixed shelf offering. The filing does not necessarily indicate that a sale has begun, or will occur in the future. The company intends to use the proceeds for working capital and general corporate purposes. The offering can include co...
Bolt Biotherapeutics press release (NASDAQ:BOLT): Q4 GAAP EPS of -$0.73 misses by $0.04. Revenue of $0.51M. Cash, cash equivalents, and marketable securities were $271.6 million as of December 31, 2021, which is expected to fund operations and the advancement of the Company's oncology product...
BDC-1001 for the treatment of patients with HER2-expressing solid tumors on track for recommended Phase 2 dose identification later in 2022; BDC-1001 combination study arm with OPDIVO® (nivolumab) progressing well Preclinical data on multiple pipeline programs will be prese...
REDWOOD CITY, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology therapeutics that combine the targeting precision of antibodies with the power of both the innate and adaptive immun...
News, Short Squeeze, Breakout and More Instantly...
Bolt Biotherapeutics Inc. Company Name:
BOLT Stock Symbol:
NASDAQ Market:
Bolt Biotherapeutics Inc. Website:
NEW YORK, July 03, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased securities of Bolt Biotherapeut...
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 147.2% to $0.705 on volume of 1,314,512,517 shares SiNtx Technologies Inc. (SINT) rose 132.0% to $0.1276 on volume of 976,185,336 shares Greenwave Technology Solutions Inc. (GWAV) r...
A look at the top 10 most actives in the United States SiNtx Technologies Inc. (SINT) rose 208.7% to $0.1698 on volume of 325,435,783 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 76.7% to $0.5039 on volume of 314,353,673 shares Greenwave Technology Solutions Inc. (GWAV) ros...